drugset / Trial / NCT00333567

Efficacy and Safety of Lumiracoxib 400 mg in Arthroscopic Knee Surgery

NCT00333567

Phase 4 Completed 110 enrolled Novartis
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is designed to investigate the efficacy and safety of a single daily dose of 400 mg lumiracoxib given pre-emptively versus post-operatively in terms of efficacy in reducing pain associated with ambulatory arthroscopic knee surgery

Timeline

Start
2006-08
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Lumiracoxib Small molecule 400 mg

Indications

No indication recorded.